Your browser doesn't support javascript.
loading
Versatile live-attenuated SARS-CoV-2 vaccine platform applicable to variants induces protective immunity.
Yoshida, Akiho; Okamura, Shinya; Torii, Shiho; Komatsu, Sayuri; Miyazato, Paola; Sasaki, Hitomi; Ueno, Shiori; Suzuki, Hidehiko; Kamitani, Wataru; Ono, Chikako; Matsuura, Yoshiharu; Takekawa, Shiro; Yamanishi, Koichi; Ebina, Hirotaka.
Affiliation
  • Yoshida A; Virus Vaccine Group, BIKEN Innovative Vaccine Research Alliance Laboratories, Institute for Open and Transdisciplinary Research Initiatives, Osaka University, Suita, Osaka, Japan.
  • Okamura S; The Research Foundation for Microbial Diseases of Osaka University, Suita, Osaka, Japan.
  • Torii S; Virus Vaccine Group, BIKEN Innovative Vaccine Research Alliance Laboratories, Institute for Open and Transdisciplinary Research Initiatives, Osaka University, Suita, Osaka, Japan.
  • Komatsu S; The Research Foundation for Microbial Diseases of Osaka University, Suita, Osaka, Japan.
  • Miyazato P; Laboratory of Virus Control, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka, Japan.
  • Sasaki H; Laboratory of Virus Control, Center for Infectious Disease Education and Research, Osaka University, Suita, Osaka, Japan.
  • Ueno S; Virus Vaccine Group, BIKEN Innovative Vaccine Research Alliance Laboratories, Institute for Open and Transdisciplinary Research Initiatives, Osaka University, Suita, Osaka, Japan.
  • Suzuki H; The Research Foundation for Microbial Diseases of Osaka University, Suita, Osaka, Japan.
  • Kamitani W; Virus Vaccine Group, BIKEN Innovative Vaccine Research Alliance Laboratories, Institute for Open and Transdisciplinary Research Initiatives, Osaka University, Suita, Osaka, Japan.
  • Ono C; The Research Foundation for Microbial Diseases of Osaka University, Suita, Osaka, Japan.
  • Matsuura Y; The Research Foundation for Microbial Diseases of Osaka University, Suita, Osaka, Japan.
  • Takekawa S; Department of Infectious Diseases and Host Defense, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan.
  • Yamanishi K; Virus Vaccine Group, BIKEN Innovative Vaccine Research Alliance Laboratories, Institute for Open and Transdisciplinary Research Initiatives, Osaka University, Suita, Osaka, Japan.
  • Ebina H; The Research Foundation for Microbial Diseases of Osaka University, Suita, Osaka, Japan.
iScience ; 25(11): 105412, 2022 Nov 18.
Article de En | MEDLINE | ID: mdl-36320329
ABSTRACT
Live-attenuated vaccines are generally highly effective. Here, we aimed to develop one against SARS-CoV-2, based on the identification of three types of temperature-sensitive (TS) strains with mutations in nonstructural proteins (nsp), impaired proliferation at 37°C-39°C, and the capacity to induce protective immunity in Syrian hamsters. To develop a live-attenuated vaccine, we generated a virus that combined all these TS-associated mutations (rTS-all), which showed a robust TS phenotype in vitro and high attenuation in vivo. The vaccine induced an effective cross-reactive immune response and protected hamsters against homologous or heterologous viral challenges. Importantly, rTS-all rarely reverted to the wild-type phenotype. By combining these mutations with an Omicron spike protein to construct a recombinant virus, protection against the Omicron strain was obtained. We show that immediate and effective live-attenuated vaccine candidates against SARS-CoV-2 variants may be developed using rTS-all as a backbone to incorporate the spike protein of the variants.
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Langue: En Journal: IScience Année: 2022 Type de document: Article Pays d'affiliation: Japon

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Langue: En Journal: IScience Année: 2022 Type de document: Article Pays d'affiliation: Japon